Voya Investment Management LLC Raises Holdings in Quest Diagnostics Incorporated $DGX

Voya Investment Management LLC boosted its position in Quest Diagnostics Incorporated (NYSE:DGX) by 0.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,758 shares of the medical research company’s stock after buying an additional 260 shares during the period. Voya Investment Management LLC’s holdings in Quest Diagnostics were worth $5,712,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. BankPlus Wealth Management LLC boosted its position in Quest Diagnostics by 2.5% in the 1st quarter. BankPlus Wealth Management LLC now owns 2,410 shares of the medical research company’s stock worth $408,000 after purchasing an additional 59 shares in the last quarter. Cullen Frost Bankers Inc. raised its stake in Quest Diagnostics by 5.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 1,059 shares of the medical research company’s stock valued at $179,000 after purchasing an additional 59 shares during the last quarter. Linden Thomas Advisory Services LLC raised its stake in Quest Diagnostics by 0.6% in the 1st quarter. Linden Thomas Advisory Services LLC now owns 11,513 shares of the medical research company’s stock valued at $1,948,000 after purchasing an additional 63 shares during the last quarter. Clarius Group LLC raised its stake in Quest Diagnostics by 4.8% in the 1st quarter. Clarius Group LLC now owns 1,421 shares of the medical research company’s stock valued at $240,000 after purchasing an additional 65 shares during the last quarter. Finally, Azzad Asset Management Inc. ADV increased its stake in shares of Quest Diagnostics by 1.7% in the 1st quarter. Azzad Asset Management Inc. ADV now owns 3,922 shares of the medical research company’s stock worth $664,000 after acquiring an additional 66 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Insider Buying and Selling at Quest Diagnostics

In other Quest Diagnostics news, SVP Patrick Plewman sold 1,975 shares of the firm’s stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $185.00, for a total value of $365,375.00. Following the completion of the sale, the senior vice president owned 15,269 shares of the company’s stock, valued at approximately $2,824,765. This trade represents a 11.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Karthik Kuppusamy sold 2,210 shares of the firm’s stock in a transaction on Thursday, July 31st. The shares were sold at an average price of $170.00, for a total value of $375,700.00. Following the completion of the sale, the senior vice president directly owned 8,450 shares of the company’s stock, valued at approximately $1,436,500. This trade represents a 20.73% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,496 shares of company stock valued at $4,278,787. Corporate insiders own 8.16% of the company’s stock.

Quest Diagnostics Price Performance

Shares of NYSE DGX opened at $183.63 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.09 and a quick ratio of 0.99. The stock has a fifty day moving average price of $176.37 and a 200 day moving average price of $173.94. Quest Diagnostics Incorporated has a 1-year low of $146.17 and a 1-year high of $185.62. The company has a market cap of $20.53 billion, a PE ratio of 21.99, a P/E/G ratio of 2.42 and a beta of 0.54.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.05. Quest Diagnostics had a return on equity of 15.24% and a net margin of 9.01%.The firm had revenue of $2.76 billion during the quarter, compared to the consensus estimate of $2.73 billion. During the same period last year, the company earned $2.35 earnings per share. The company’s revenue for the quarter was up 15.2% on a year-over-year basis. Quest Diagnostics has set its FY 2025 guidance at 9.630-9.830 EPS. Sell-side analysts forecast that Quest Diagnostics Incorporated will post 9.7 EPS for the current year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, October 20th. Investors of record on Friday, October 3rd will be issued a dividend of $0.80 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $3.20 annualized dividend and a dividend yield of 1.7%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 38.32%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on DGX shares. Robert W. Baird reissued a “neutral” rating and set a $194.00 price target on shares of Quest Diagnostics in a research report on Monday, August 25th. William Blair reiterated an “outperform” rating on shares of Quest Diagnostics in a research note on Wednesday, July 23rd. UBS Group cut their price target on shares of Quest Diagnostics from $176.00 to $175.00 and set a “neutral” rating on the stock in a research note on Friday, July 18th. Baird R W lowered shares of Quest Diagnostics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 25th. Finally, Wall Street Zen lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Sunday, August 10th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $186.00.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.